Co-relation of Portal Vein Tumour Thrombus Response With Survival Function Following Robotic Radiosurgery in Vascular Invasive Hepatocellular Carcinoma
- PMID: 38680618
- PMCID: PMC11053332
- DOI: 10.1016/j.jceh.2024.101404
Co-relation of Portal Vein Tumour Thrombus Response With Survival Function Following Robotic Radiosurgery in Vascular Invasive Hepatocellular Carcinoma
Abstract
Background/aims: The aim of this study was to prospectively evaluate stereotactic body radiotherapy (SBRT) with robotic radiosurgery in hepatocellular carcinoma patients with macrovascular invasion (HCC-PVT).
Materials and methods: Patients with inoperable HCC-PVT, good performance score (PS0-1) and preserved liver function [up to Child-Pugh (CP) B7] were accrued after ethical and scientific committee approval [Clinical trial registry-India (CTRI): 2022/01/050234] for treatment on robotic radiosurgery (M6) and planned with Multiplan (iDMS V2.0). Triple-phase contrast computed tomography (CT) scan was performed for contouring, and gross tumour volume (GTV) included contrast-enhancing mass within main portal vein and adjacent parenchymal disease. Dose prescription was as per risk stratification protocol (22-50 Gy in 5 fractions) while achieving the constraints of mean liver dose <15 Gy, 800 cc liver <8 Gy and the duodenum max of <24 Gy). Response assessment was done at 2 months' follow-up for recanalization. Patient- and treatment-related factors were evaluated for influence in survival function.
Results: Between Jan 2017 and May 2022, 318 consecutive HCC with PVT patients were screened and 219 patients were accrued [male 92%, CP score: 5-7 90%, mean age: 63 years (38-85 yrs), Cancer of the Liver Italian Program <3: 84 (40%), 3-6117 (56%), infective aetiology 9.5%, performance status (PS): 0-37%; 1-56%]. Among 209 consecutive patients accrued for SBRT treatment (10 patients were excluded after accrual due to ascites and decompensation), 139 were evaluable for response assessment (>2 mo follow-up). At mean follow-up of 12.21 months (standard deviation: 10.66), 88 (63%) patients expired and 51 (36%) were alive. Eighty-two (59%) patients had recanalization of PVT (response), 57 (41%) patients did not recanalize and 28 (17%) had progressive/metastatic disease prior to response evaluation (<2 months). Mean overall survival (OS) in responders and non-responders were 18.4 [standard error (SE): 2.52] and 9.34 month (SE 0.81), respectively (P < 0.001). Mean survival in patients with PS0, PS1 and PS2 were 17, 11.7 and 9.7 months (P = 0.019), respectively. OS in partial recanalization, bland thrombus and complete recanalization was 12.4, 14.1 and 30.3 months, respectively (P-0.002). Adjuvant sorafenib, Barcelona Clinic Liver Classification stage, gender, age and RT dose did not influence response to treatment. Recanalization rate was higher in good PS patients (P-0.019). OS in patients with response to treatment, in those with no response to treatment, in those who are fit but not accrued and in those who are not suitable were 18.4, 9.34, 5.9 and 2.6 months, respectively (P-<0.001). Thirty-six of 139 patients (24%) had radiation-induced liver disease (RILD) [10 (7.2%) had classic RILD & 26 (19%) had non-classic RILD]. Derangement in CP score (CP score change) by more than 2 was seen in 30 (24%) within 2-month period after robotic radiosurgery. Eighteen (13%) had unplanned admissions, two patients required embolization due to fiducial-related bleeding and 20 (14%) had ascites, of which 9 (6%) patients required abdominocentesis.
Conclusion: PVT response or recanalization after SBRT is a statistically significant prognostic factor for survival function in HCC-PVT.
Keywords: hepatocellular carcinoma; portal vein thrombosis; recanalization; robotic radiosurgery.
© 2024 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study.Indian J Gastroenterol. 2021 Aug;40(4):389-401. doi: 10.1007/s12664-021-01172-w. Epub 2021 Oct 25. Indian J Gastroenterol. 2021. PMID: 34694581
-
Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma.Cancer. 2005 Jun 1;103(11):2419-26. doi: 10.1002/cncr.21043. Cancer. 2005. PMID: 15822130
-
Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma.Korean J Intern Med. 2018 Nov;33(6):1093-1102. doi: 10.3904/kjim.2016.412. Epub 2017 Aug 28. Korean J Intern Med. 2018. PMID: 28844122 Free PMC article.
-
Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.J Med Imaging Radiat Oncol. 2021 Jun;65(3):365-373. doi: 10.1111/1754-9485.13184. Epub 2021 Apr 22. J Med Imaging Radiat Oncol. 2021. PMID: 33890425 Review.
-
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines.Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):337-351. doi: 10.1016/j.ijrobp.2023.08.015. Epub 2023 Aug 18. Int J Radiat Oncol Biol Phys. 2024. PMID: 37597757 Review.
References
-
- Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. - PubMed
-
- Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet Lond Engl. 2003 Dec 6;362:1907–1917. - PubMed
-
- Forner A., Ayuso C., Varela M., et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. Cancer. 2009;115:616–623. - PubMed
-
- Rimassa L., Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9:739–745. - PubMed
-
- Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous